Cholesterol and lipid-regulatory gene network

The cholesterol and lipid-regulatory gene network is a sophisticated biological system responsible for maintaining cellular and systemic lipid balance through the coordinated action of transcription factors, enzymes, and transport proteins (Brown & Goldstein, 1997). At the core of this network are the Sterol Regulatory Element-Binding Proteins (SREBPs), which act as master regulators by sensing intracellular sterol levels and activating the transcription of genes required for cholesterol and fatty acid biosynthesis, such as HMG-CoA reductase (HMGCR) and the Low-Density Lipoprotein Receptor (LDLR) (Horton et al., 2002). Other critical components include Liver X Receptors (LXRs), which promote cholesterol efflux, and Peroxisome Proliferator-Activated Receptors (PPARs), which regulate fatty acid oxidation and triglyceride levels (Zelcer & Tontonoz, 2006). Dysregulation of this network, often due to genetic factors or high-fat diets, leads to pathological conditions such as hypercholesterolemia and atherosclerosis, which are major drivers of cardiovascular disease (Goldstein & Brown, 2015). Therapeutic strategies involve targeting specific nodes within the network to lower circulating lipids, most notably through the use of statins to inhibit HMGCR or monoclonal antibodies to inhibit PCSK9, thereby increasing LDL clearance from the blood. Understanding the network's interconnectedness is vital for developing multi-target therapies and managing metabolic disorders like nonalcoholic fatty liver disease.

Other names

Lipid metabolism pathwayCholesterol homeostasis networkSREBP regulatory circuitLipid-regulatory gene network

Pharmacological agents modulate this network by targeting specific nodes: statins inhibit HMG-CoA reductase to block cholesterol synthesis; PCSK9 inhibitors prevent LDL receptor degradation; ezetimibe blocks intestinal cholesterol absorption; and fibrates activate PPAR-alpha to increase fatty acid oxidation and HDL synthesis.